Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma.

Autor: Yohay S; Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Oloyede T; Center for International Blood and Marrow Transplantation, Milwaukee, Wisconsin, USA., Kim S; Center for International Blood and Marrow Transplantation, Milwaukee, Wisconsin, USA., Fang X; Yale University, New Haven, Connecticut, USA., Dhakal B; Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Aijaz A; We Care Scan Center, Srinagar, Kashmir, India., Mohan M; Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Narra R; Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Pasquini M; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.; Center for International Blood and Marrow Transplantation, Milwaukee, Wisconsin, USA., D'Souza A; Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Hamadani M; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.; Center for International Blood and Marrow Transplantation, Milwaukee, Wisconsin, USA., Freeman CL; Moffitt Cancer Center, Tampa, Florida, USA., Akhtar OS; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.; Center for International Blood and Marrow Transplantation, Milwaukee, Wisconsin, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Oct 13. Date of Electronic Publication: 2024 Oct 13.
DOI: 10.1111/bjh.19811
Abstrakt: In patients with multiple myeloma (MM) not-eligible for autologous haematopoietic cell transplantation (autoHCT), a simplified frailty index (SFI) identifies frail patients at risk for poor outcomes, but data are limited for transplant-eligible patients. In this registry-based retrospective study, we used an adapted version of the SFI to determine the prevalence of frailty in patients ≥65 years of age with MM undergoing autoHCT. Out of 5563 patients, 37.9% of patients were classified as frail and although they had increased non-relapse mortality (NRM) and inferior overall survival, the NRM at 100 days remained low (<2%) compared with non-frail patients.
(© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: